<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31521" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Rosuvastatin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bajaj</surname>
            <given-names>Tushar</given-names>
          </name>
          <aff>University of Chicago</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Giwa</surname>
            <given-names>Al O.</given-names>
          </name>
          <aff>Icahn School of Medicine at Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tushar Bajaj declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Al Giwa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>23</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31521.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Rosuvastatin is a statin medication used as a lipid-lowering agent. The FDA-approved indications are homozygous familial hypercholesterolemia, hyperlipidemia, mixed dyslipidemia, primary dysbetalipoproteinemia, hypertriglyceridemia, and prevention of cardiovascular disease. The non-FDA-approved uses are in non-cardioembolic stroke, secondary prevention in transient ischemic attack (TIA), and perioperative therapy for cardiac risk reduction in noncardiac surgeries. This activity outlines the indications, mechanism of action, methods of administration, important adverse effects, contraindications, and monitoring, of rosuvastatin, so providers can direct patient therapy in treating hyperlipidemia as part of the interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of rosuvastatin.</p></list-item><list-item><p>Describe the potential adverse effects for patients taking rosuvastatin.</p></list-item><list-item><p>Review the appropriate monitoring for patients on rosuvastatin.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance rosuvastatin where it is indicated and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31521&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31521">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31521.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Rosuvastatin is a statin medication used as a lipid-lowering agent. The FDA-approved indications are homozygous familial hypercholesterolemia, hyperlipidemia, mixed dyslipidemia, primary dysbetalipoproteinemia, hypertriglyceridemia, and prevention of cardiovascular disease. The non-FDA-approved uses are in non-cardioembolic stroke, secondary prevention in transient ischemic attack (TIA), and perioperative therapy for cardiac risk reduction in noncardiac surgeries.</p>
      </sec>
      <sec id="article-31521.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The mechanism of action of rosuvastatin is inhibition of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase. This enzyme is the rate-limiting step in cholesterol synthesis, which reduces the production of mevalonic acid from HMG-CoA. Furthermore, this results in an increase of low-density lipoprotein receptors on hepatocyte membranes and stimulation of low-density lipoprotein catabolism. HMG-CoA reductase inhibitors also decrease levels of high sensitivity C-reactive protein (CRP). They also possess pleiotropic properties, including inhibition of platelet aggregation, anticoagulant effects, reduced inflammation at the site of a coronary plaque, and improved endothelial function.<xref ref-type="bibr" rid="article-31521.r1">[1]</xref><xref ref-type="bibr" rid="article-31521.r2">[2]</xref></p>
        <p>Rosuvastatin is not extensively metabolized, with approximately 10% of a radiolabeled dose being recoverable as a metabolite. The pharmacokinetic properties of statin medications vary; however, rosuvastatin is unique in that its half-life is 19 hours, bioavailability is 20%, protein binding is 88%, possesses hydrophilic solubility, metabolized by CYP2C9, and primarily fecally excreted (90%) with only 10% urinary excretion.<xref ref-type="bibr" rid="article-31521.r3">[3]</xref></p>
      </sec>
      <sec id="article-31521.s4" sec-type="Administration">
        <title>Administration</title>
        <p>The administration of rosuvastatin is via capsule or tablet. The capsule can be administered orally or via a nasogastric tube. The oral route can be taken with or without food, at any time of the day, and should be swallowed whole. The capsule should never be crushed or chewed. If opening the capsule, it is recommended to empty the contents into one teaspoonful of applesauce and then swallowed immediately without chewing.</p>
        <p>For administration with a nasogastric tube, the capsule can be opened, emptied into a 60 ml&#x000a0;catheter-tipped syringe. The recommendation is to add 40 milliliters of water, replace the plunge, shake the syringe for 15 seconds. Then attach the syringe to at least a 16 French nasogastric tube and administer with an additional flush of the tube with 20 milliliters of water. The mixture needs to be used promptly after preparation.</p>
        <p>Dosage for the oral tablet is the same for the generic and trade name:</p>
        <list list-type="bullet">
          <list-item>
            <p>5 mg, 10 mg, 20 mg, 40 mg</p>
          </list-item>
        </list>
        <p>Dosage recommendations: Dosing is individualized based on the low-density lipoprotein (LDL) levels at baseline and the goal of therapy. The patient&#x02019;s response and medication adherence is an important determinant of therapeutic success. Adjustments should be made at a regular interval of four weeks or more depending on the underlying pathology of the disease and whether the treatment is for primary versus secondary prevention. Due to the risk&#x000a0;of significant drug-drug interactions, the adjustment in dosing should be part of medication reconciliation with the current literature and a pharmacist. In renal impairment, if the creatinine clearance is greater or equal to 30 ml/minute, then no dosage adjustment is necessary; however, if lower than this cutoff, the recommendation is to start the lowest possible dose of 5 mg once daily with a maximum dosage of 10 mg per day.</p>
      </sec>
      <sec id="article-31521.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Clinically Relevant Adverse Effects<xref ref-type="bibr" rid="article-31521.r4">[4]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Creatinine kinase of greater than ten times the upper limit of normal</p>
          </list-item>
          <list-item>
            <p>Severe myopathy</p>
          </list-item>
          <list-item>
            <p>Rhabdomyolysis</p>
          </list-item>
          <list-item>
            <p>AST or ALT elevations of greater than three times the upper limit of normal</p>
          </list-item>
          <list-item>
            <p>Renal failure</p>
          </list-item>
        </list>
        <p>Rare adverse effects include diabetes mellitus, hematuria, proteinuria, and hypersensitivity.</p>
        <p>Other reported symptomatic adverse effects include headache, dizziness, nausea, constipation, interstitial cystitis, arthralgia, and weakness.</p>
        <p>Drug-Drug Interactions:</p>
        <list list-type="order">
          <list-item>
            <p>The following medications may enhance the myopathic effect of rosuvastatin: acipimox, bezafibrate, ciprofibrate, colchicine, daptomycin, fenofibrate, fusidic acid, gemfibrozil, niacin, niacinamide, raltegravir, red yeast rice, rupatadine.</p>
          </list-item>
          <list-item>
            <p>The following medications may decrease the serum concentration of rosuvastatin: antacids, apalutamide, elagolix, eslicarbazepine.</p>
          </list-item>
          <list-item>
            <p>The following medications may increase the serum concentrations of rosuvastatin: asunaprevir, clopidogrel, cobicistat, cyclosporine, daclatasvir, dasabuvir, dronedarone, elbasvir, eltrombopag, eluxadoline, fostamatinib, glecaprevir, pibrentasvir, grazoprevir, itraconazole, ledipasvir, letermovir, ombitasvir, paritaprevir, ritonavir, osimertinib, protease inhibitors, simeprevir, teriflunomide, velpatasvir, voxilaprevir.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31521.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>As with many drugs, if the patient has a hypersensitivity to rosuvastatin or any component of the drug formulation, they must discontinue the drug. Other contraindications are listed below<xref ref-type="bibr" rid="article-31521.r5">[5]</xref><xref ref-type="bibr" rid="article-31521.r6">[6]</xref>:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Pregnancy (pregnancy category X)</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>There are reports of congenital anomalies</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Breastfeeding</p>
          </list-item>
          <list-item>
            <p>Active liver disease</p>
          </list-item>
          <list-item>
            <p>Unexplained persistent elevations of serum transaminases</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31521.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The following monitoring parameters are from the American College of Cardiology and the American Heart Association Cholesterol Guideline Recommendations.<xref ref-type="bibr" rid="article-31521.r7">[7]</xref></p>
        <p>Creatinine phosphokinase (CPK) levels should not be routinely measured; however, the clinician can base special considerations for measuring CPK on family history of statin intolerance, drug-drug interactions leading to increased risk of myopathy, or other clinical presentations that create a high index of suspicion of myopathy.</p>
        <p>Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, and total bilirubin levels do not need to be measured routinely. Only if symptoms suggest underlying hepatotoxicity during therapy, it may be beneficial to obtain these levels.</p>
        <p>Lipid panel testing, including low-density lipoprotein, high-density lipoprotein, triglycerides, and total cholesterol, should be obtained on an initial visit to establish a baseline. Thereafter, a fasting lipid profile should be obtained within four to twelve weeks after initiation or dose adjustment. Furthermore, after receiving these initial&#x000a0;two levels, further fasting lipid profiles are only necessary every three to twelve months or as clinically indicated. If two consecutive low-density lipoprotein levels are less than 40 milligrams per deciliter, the clinician should decrease the dose.</p>
      </sec>
      <sec id="article-31521.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The most common toxic side effect of rosuvastatin is myalgia. If the patient has mild to moderate muscle symptoms, the drug should be discontinued to evaluate other causes of myalgia. If there is a resolution of the underlying etiology, the patient can restart the original or a lower dose of rosuvastatin; however, if symptoms reoccur for a second time, then discontinue rosuvastatin indefinitely. Switching to a different statin medication at a lower dose may relieve muscle symptoms.</p>
        <p>It is clear that if severe muscle symptoms or fatigue occur, the provider should discontinue the medication and order a creatinine phosphokinase level, serum creatinine, and a urinalysis to evaluate for myoglobinuria.</p>
      </sec>
      <sec id="article-31521.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Rosuvastatin is a widely used medication for serum lipid-lowering. The drug is known to be effective for elevated lipid levels and the prevention of cardiovascular disease. Prescribing and monitoring the patient will require&#x000a0;interprofessional collaboration and communication&#x000a0;between the clinicians (including NPs and PAs), pharmacists, nursing staff, and other subspecialties such as cardiologists who may have a role in adjusting the dosage of the medication. Monitoring for the effect of the drug and dose adjustment is best accomplished via an interprofessional approach, although it is manageable by a single provider. The drug does have multiple drug-drug interactions; therefore, it is helpful for pharmacists to check and flag any interactions. If any drug-drug interactions are present, the pharmacist must notify the provider immediately. Nursing also bears responsibility for monitoring for adverse reactions, helping assess therapeutic effectiveness, offering counsel to the patient, and serving as a&#x000a0;liaison between the pharmacist and other providers and the prescriber. The prescribing provider should determine the risks versus benefits of the medication in conjunction with the patient after an informed consent discussion with shared decision making. Only with a collaborative interprofessional team approach can rosuvastatin therapy be optimized to deliver the appropriate therapeutic results for the patient. [Level 5]</p>
      </sec>
      <sec id="article-31521.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31521&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31521">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31521/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31521">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-31521.s11">
        <title>References</title>
        <ref id="article-31521.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Denus</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spinler</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Early statin therapy for acute coronary syndromes.</article-title>
            <source>Ann Pharmacother</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>36</volume>
            <issue>11</issue>
            <fpage>1749</fpage>
            <page-range>1749-58</page-range>
            <pub-id pub-id-type="pmid">12398573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31521.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ray</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2005</year>
            <month>Oct</month>
            <day>18</day>
            <volume>46</volume>
            <issue>8</issue>
            <fpage>1425</fpage>
            <page-range>1425-33</page-range>
            <pub-id pub-id-type="pmid">16226165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31521.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schachter</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.</article-title>
            <source>Fundam Clin Pharmacol</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>117</fpage>
            <page-range>117-25</page-range>
            <pub-id pub-id-type="pmid">15660968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31521.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kostapanos</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Milionis</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Elisaf</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.</article-title>
            <source>Am J Cardiovasc Drugs</source>
            <year>2010</year>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-28</page-range>
            <pub-id pub-id-type="pmid">20104931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31521.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Godfrey</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Erramouspe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cleveland</surname>
                <given-names>KW</given-names>
              </name>
            </person-group>
            <article-title>Teratogenic risk of statins in pregnancy.</article-title>
            <source>Ann Pharmacother</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>46</volume>
            <issue>10</issue>
            <fpage>1419</fpage>
            <page-range>1419-24</page-range>
            <pub-id pub-id-type="pmid">23032657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31521.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lecarpentier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Morel</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Fournier</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Elefant</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chavatte-Palmer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tsatsaris</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Statins and pregnancy: between supposed risks and theoretical benefits.</article-title>
            <source>Drugs</source>
            <year>2012</year>
            <month>Apr</month>
            <day>16</day>
            <volume>72</volume>
            <issue>6</issue>
            <fpage>773</fpage>
            <page-range>773-88</page-range>
            <pub-id pub-id-type="pmid">22480340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31521.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grundy</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Beam</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Birtcher</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>de Ferranti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Faiella-Tommasino</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Forman</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Hlatky</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lopez-Pajares</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ndumele</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Orringer</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Peralta</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Saseen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Yeboah</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2019</year>
            <month>Jun</month>
            <day>18</day>
            <volume>139</volume>
            <issue>25</issue>
            <fpage>e1082</fpage>
            <page-range>e1082-e1143</page-range>
            <pub-id pub-id-type="pmid">30586774</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
